Polish and European generics groups view opportunities for biosimilars

29 October 2014

The European Biosimilars Group – a sector group of the European Generic medicines Association (EGA), together with the Polish Generic Medicines Association (PZPPF) organized a multi-stakeholder event in Warsaw this week gathering patient and hospital representatives, health economists, prescribers, industry delegates and research institutes to discuss the challenges and opportunities offered by biosimilar medicines.

Biosimilar medicines play an important role in Poland by offering cost-effective equivalent treatments, contributing to the reliable supply of medicines while preserving health care budgets.

According to the recent GfK Market Access study (The Pharma Letter September 15), a sustainable national policy framework for biosimilar medicines should include: unbiased education and information to stakeholders; incentivization of early use combined with sustainable pricing; collecting evidence about real world experience; and transparent procurement that does not delay time to market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK